Xenon Pharmaceuticals (XENE) Misses Q3 EPS by 25c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. INTC
2. AMZN
3. COIN
4. RDDT
5. PINS
6. FSLR
7. DASH
8. SYK
9. SBUX
10. FND

Go back to Xenon Pharmaceuticals (XENE) Misses Q3 EPS by 25c

Xenon Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update

November 10, 2015 4:30 PM EST

Progress Includes Initiation of XEN801 Phase 1 Clinical Trial and Achievement of Milestones in Genentech Nav1.7 Clinical Program and Pain Genetics Collaboration

Conference Call/Webcast Today at 5:00 p.m. Eastern Time

BURNABY, British Columbia, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quarter ended September 30, 2015 and provided a corporate update.

Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, said, "We are pleased with our progress in the third quarter... More